Data / New clinical trials / Non-alcoholic Fatty Liver Disease

Non-alcoholic Fatty Liver Disease trials: 146 new

Name: New Non-alcoholic Fatty Liver Disease clinical trials
Creator: SpecStream
License: https://creativecommons.org/licenses/by/4.0/

The full list. New Non-alcoholic Fatty Liver Disease clinical trials: 146 rows for $7.30, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. The list gains about 6 rows a month. The new rows come each week by email, $19 a month.

Get this list free

$10 of credit on sign-up, no card. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The weekly rows run until you cancel, from the link in each delivery. To get the new rows in your own tools, use SpecStream on Zapier. The rows on this page are a sample.

For agents and scripts: this list is ordered at https://specstream.ai/data/clinical-trials/condition/non-alcoholic-fatty-liver-disease, and every list with its row count and price is at https://specstream.ai/data/lists.json.

Updated November 6, 2026. Source: ClinicalTrials.gov API v2 (U.S. National Library of Medicine).

146 clinical studies in Non-alcoholic Fatty Liver Disease were first posted on ClinicalTrials.gov from November 14, 2024 to November 6, 2026; 34 have an industry sponsor and 90 are recruiting or about to. The newest, NCT07922720, was posted on November 6, 2026: Efficacy of Carnitine Complex in Improving Hepatic Steatosis in Potential Liver Donors (Samsung Medical Center).

The request: Every new Non-alcoholic Fatty Liver Disease clinical trial on ClinicalTrials.gov, with the sponsor, phase, sites and the listed contact.

Get new trials like these Watch a sponsor

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

146New trials
34Industry sponsored
90Recruiting or not yet
November 6, 2026Latest posted

Newest trials

The newest 100 of 146, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

First posted	NCT ID	Title	Sponsor	Phase	Status	Conditions	Enrollment	Countries	Source
November 6, 2026	NCT07922720	Efficacy of Carnitine Complex in Improving Hepatic Steatosis in Potential Liver Donors	Samsung Medical Center	Not applicable	Not yet recruiting	Hepatic Steatosis, Fatty Liver, Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatotic Liver...	40		clinicaltrials.gov
November 4, 2026	NCT07915596	Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	Observational	Completed	Type 2 Diabetes Mellitus, Nonalcoholic Fatty Liver Disease	792	Bangladesh	clinicaltrials.gov
October 28, 2026	NCT07900100	Evaluating the Safety and Efficacy of Rupatadine in the Treatment of Nonalcoholic Fatty Liver Disease Patients.	Tanta University	Phase 2/3	Not yet recruiting	NAFLD (Nonalcoholic Fatty Liver Disease)	60	Egypt	clinicaltrials.gov
October 28, 2026	NCT07900087	Evaluating the Safety and Efficacy of Roflumilast in the Treatment of Nonalcoholic Fatty Liver Disease Patients	Tanta University	Phase 2/3	Not yet recruiting	NAFLD (Nonalcoholic Fatty Liver Disease)	60	Egypt	clinicaltrials.gov
October 21, 2026	NCT07884903	Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks	Shanxi Bethune Hospital	Observational	Not yet recruiting	Obesity & Overweight, Diabetes Mellitus, Type 2, Hypertension, Non-alcoholic Fatty Liver Disease (MASLD)...	25,974	China	clinicaltrials.gov
October 19, 2026	NCT07881796	Effect of Dapagliflozin on Metabolic Parameters in Patients With Non-Alcoholic Fatty Liver Disease	Shalamar Hospital	Not applicable	Completed	Non-Alcoholic Fatty Liver Disease	146	Pakistan	clinicaltrials.gov
October 14, 2026	NCT07873229	DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine	Eccogene	Phase 1	Not yet recruiting	Steatohepatitis, Nonalcoholic, Osteo Arthritis	40	Australia	clinicaltrials.gov
October 6, 2026	NCT07861594	Lifestyle, Dietary Patterns, and Cardiometabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease Among People Living With...	Assiut University	Observational	Not yet recruiting	Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), HIV Infections, Non-Alcoholic Fatty Liver Disease...	250		clinicaltrials.gov
October 2, 2026	NCT07854782	Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	Regeneron Pharmaceuticals	Phase 3	Recruiting	Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD	1,500	United States	clinicaltrials.gov
September 22, 2026	NCT07834905	Nutritional Indices and Inflammatory Markers in MASLD	Assiut University	Observational	Not yet recruiting	Liver Fibrosis, Malnutrition, Non-Alcoholic Fatty Liver Disease	180		clinicaltrials.gov
September 22, 2026	NCT07833514	Misocholic Tablets for Non-Viral Elevated Liver Enzymes	Hanoi Medical University	Phase 3	Not yet recruiting	Alcohol-Related Liver Disease, Drug-Induced Liver Injury, Non-alcoholic Fatty Liver Disease	60	Vietnam	clinicaltrials.gov
September 22, 2026	NCT07832994	Metaboic Syndrome and Fatty Liver in Celiac Disease Females: Reponse to Exercise in Adolescents	Cairo University	Not applicable	Recruiting	Celiac Disease, Metabolic Syndrome, Non Alcoholic Fatty Liver	40	Egypt	clinicaltrials.gov
September 18, 2026	NCT07827430	Impact of Overt and Subclinical Hypothyroidism on Liver Fibrosis in Patients With MASLD	Assiut University	Observational	Not yet recruiting	Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hypothyroidism, Liver...	120		clinicaltrials.gov
September 17, 2026	NCT07825467	Brown Adipose Tissue Activity and NAFLD Progression	Renmin Hospital of Wuhan University	Observational	Completed	Nonalcoholic Fatty Liver Disease	96	China	clinicaltrials.gov
September 15, 2026	NCT07820800	NMR Metabolomics-Based Risk Assessment and Stratified Digital Health Interventions in Middle-Aged Adults (PREMAP)	University of Eastern Finland	Not applicable	Recruiting	Type 2 Diabetes, Coronary Heart Disease, Myocardial Infarction, Cerebrovascular Disease, Stroke, Chronic Kidney...	1,400	Finland	clinicaltrials.gov
September 1, 2026	NCT07797101	Body-weight Reduction Effect on Portal Hypertension in Compensated Cirrhosis	The Second Affiliated Hospital of Chongqing Medical University	Not applicable	Not yet recruiting	Cirrhosis, Portal Hypertension, Fatty Liver Disease, GLP-1	50		clinicaltrials.gov
August 28, 2026	NCT07793279	Hypothyroidism and Liver Fibrosis Severity in MASLD	Assiut University	Observational	Not yet recruiting	Metabolic Dysfunction-Associated Steatotic Liver Disease, Hypothyroidism, Liver Cirrhosis, Non-Alcoholic Fatty Liver...	85		clinicaltrials.gov
August 20, 2026	NCT07775638	Detecting Liver Fibrosis in Patients At-risk	Helse Stavanger HF	Observational	Not yet recruiting	Fatty Liver, NAFLD - Non-Alcoholic Fatty Liver Disease, Nash, MASLD (Metabolic Dysfunction-Associated Steatotic Liver...	1,200	Norway	clinicaltrials.gov
August 17, 2026	NCT07768956	Effects of Turkish Coffee and Green Tea in Fatty Liver Disease	Okan University	Not applicable	Completed	Non Alcoholic Fatty Liver Disease	47	Turkey (Türkiye)	clinicaltrials.gov
August 17, 2026	NCT07768657	Improvement in Hepatic Function Through Sumac (Rhus Coriaria L.) Supplement Along With a Calorie-restricted Diet for the Management of...	University of Lahore	Not applicable	Completed	Liver Biomarkers, Lipid Profile, Glucose, Insulin	102	Pakistan	clinicaltrials.gov
July 31, 2026	NCT07740109	The Effects of 5-methyltetrahydrofolate Supplementation in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease	Tabriz University of Medical Sciences	Not applicable	Not yet recruiting	Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD), MASLD - Metabolic Dysfunction-Associated...	44	Iran	clinicaltrials.gov
July 28, 2026	NCT07731360	Non-Invasive Diagnostic Panel for MASLD in Children With Obesity	Kayseri City Hospital	Observational	Not yet recruiting	Metabolic Dysfunction-Associated Steatotic Liver Disease, Pediatric Obesity, Insulin Resistance Syndrome	180	Turkey (Türkiye)	clinicaltrials.gov
July 28, 2026	NCT07730905	Analysis of Renal Impairment Characteristics and High-Risk Factors in Chronic Hepatitis B Patients on Long-Term Oral Nucleos(t)Ide Analogues	Foshan Hospital of Traditional Chinese Medicine	Observational	Completed	Non-alcoholic Fatty Liver Disease, Renal Function Impairment	300	China	clinicaltrials.gov
July 24, 2026	NCT07726368	Study of ECC4703 With Sulfasalazine and Pitavastatin	Eccogene	Phase 1	Recruiting	Non-alcoholic Fatty Liver Disease (NAFLD), Dyslipidaemia	40	Australia	clinicaltrials.gov
July 21, 2026	NCT07716384	Wearable Patch Ultrasound Probe for Diagnosis of Liver Stiffness	Second Affiliated Hospital of Xi'an Jiaotong University	Observational	Not yet recruiting	Liver Fibrosis, Liver Cirrhosis, NAFLD (Nonalcoholic Fatty Liver Disease), HEPATITIS B CHRONIC	150		clinicaltrials.gov
July 20, 2026	NCT07713992	Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease...	Tianjin Medical University	Not applicable	Not yet recruiting	Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus	72		clinicaltrials.gov
July 13, 2026	NCT07697313	High-intensity Interval Training Versus Moderate Intensity Continuous Training on Gut Microbiota in Non-alcoholic Fatty Liver	Horus University	Not applicable	Not yet recruiting	Non-alcoholic Fatty Liver	60	Egypt	clinicaltrials.gov
July 9, 2026	NCT07693777	A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia	Zhejiang Doer Biologics Co., Ltd.	Phase 3	Not yet recruiting	Severe Hypertriglyceridemia (sHTG), Hypertriglyceridemia	480	China	clinicaltrials.gov
June 23, 2026	NCT07662356	Clinical Course and Biomarkers Associated With Nonalcoholic Fatty Liver Disease (NAFLD) in Chinese Patients With Obesity	Chinese University of Hong Kong	Observational	Recruiting	Nonalcoholic Fatty Liver Disease (NAFLD)	200	Hong Kong	clinicaltrials.gov
June 22, 2026	NCT07658755	Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme	Hospital General Universitario Gregorio Marañon	Observational	Recruiting	Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis, Non-alcoholic Fatty Liver Disease NAFLD, Type...	3,000	Spain	clinicaltrials.gov
June 12, 2026	NCT07644936	Molecular Characterization of Autoimmune Hepatitis: A Lipidomic Approach	Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis	Observational	Not yet recruiting	Autoimmune Hepatitis, Non-Alcoholic Fatty Liver Disease	24	Italy	clinicaltrials.gov
June 9, 2026	NCT07637006	Linzhi Jianghuang Fufang Huoxue Anshen Capsule for Non-alcoholic Fatty Liver	Hong Kong Baptist University	Phase 2	Not yet recruiting	Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)	180		clinicaltrials.gov
June 8, 2026	NCT07631637	Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)	Regeneron Pharmaceuticals	Phase 2	Recruiting	Metabolic Dysfunction-Associated Steatohepatitis, MASH	360	Puerto Rico, United Kingdom, United States	clinicaltrials.gov
June 3, 2026	NCT07622680	Comparative Effects of Mediterranean and DASH Diet on Hepatic Function	University of Lahore	Not applicable	Completed	NAFLD (Nonalcoholic Fatty Liver Disease), Hep A	75	Pakistan	clinicaltrials.gov
May 20, 2026	NCT07599241	Additive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver Issues	Cairo University	Not applicable	Recruiting	Subclinical hypothyroïdism, Non-Alcoholic Fatty Liver Disease, Primary Open Angle Glaucoma	40	Egypt	clinicaltrials.gov
May 12, 2026	NCT07581951	A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASH	Haisco Pharmaceutical Group Co., Ltd.	Phase 3	Recruiting	MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH (Non-Alcoholic Steatohepatitis)	886	China	clinicaltrials.gov
May 12, 2026	NCT07580482	The Referral to Hepatology Can be Improved Through an Electronic Medical Record (EMR)-Based Best Practice Alert (BPA) for an Appropriate...	University of Kansas Medical Center	Not applicable	Completed	Liver Diseases, Liver Fat, Diabetes Mellitus, Type 2, Non-Alcoholic Steatohepatitis	30	United States	clinicaltrials.gov
May 6, 2026	NCT07570810	Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM	Shanghai Jiao Tong University School of Medicine	Not applicable	Not yet recruiting	Type 2 Diabetes, Obesity, Non-alcoholic Fatty Liver Disease	30		clinicaltrials.gov
May 4, 2026	NCT07564947	Impact of Ganoderma Lucidum on NRF2 Levels and Antioxidant Status in Metabolic Asscociated Fatty Liver Disease (GL-MAFLD-NRF2 Study)	University of Agriculture, Peshawar	Not applicable	Enrolling by invitation	MAFLD, Fatty Liver, Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD, Fatty Liver, Nonalcoholic, Fatty Liver...	40	Pakistan	clinicaltrials.gov
April 28, 2026	NCT07553663	Evaluating the Pharmacokinetics and Safety of Miricorilant	Corcept Therapeutics	Phase 1	Completed	Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic...	14	United States	clinicaltrials.gov
April 14, 2026	NCT07527910	A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD	Regeneron Pharmaceuticals	Phase 2	Recruiting	Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	204	United States	clinicaltrials.gov
April 9, 2026	NCT07518784	Accurate Point of Care Liver Disease Diagnostics (Phase 2)	University of California, San Diego	Observational	Completed	MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), NAFLD, NAFLD (Nonalcoholic Fatty Liver Disease)	26	United States	clinicaltrials.gov
April 7, 2026	NCT07514377	JiGenerations Health Cohort Study：Parental Exposure and Intergenerational Health in China	National Research Institute for Family Planning, China	Observational	Active not recruiting	Environmental Exposure, Fertility, Health Problems in Pregnancy, Adverse Pregnancy Outcomes, Birth Defects, Child...	100,000	China	clinicaltrials.gov
March 27, 2026	NCT07497750	Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver Disease - A...	University Hospital, Toulouse	Not applicable	Not yet recruiting	Non Alcoholic Fatty Liver Disease	216	France	clinicaltrials.gov
March 27, 2026	NCT07493967	Short and Long Term Clinical and Patient-Reported Outcomes Associated With Intragastric Balloon Placement in Patients With Nonalcoholic...	Methodist Health System	Observational	Enrolling by invitation	NAFLD	200	United States	clinicaltrials.gov
March 19, 2026	NCT07481734	Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)	Hudson Biotech	Phase 2	Recruiting	Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis	120	China	clinicaltrials.gov
February 12, 2026	NCT07407634	A Randomized, Double-blind, Single-center Phase I/IIa Study of XTYW007 Tablets in Subjects.	Xi'an Xintong Pharmaceutical Research Co.,Ltd.	Early phase 1	Not yet recruiting	Non-Alcoholic Fatty Liver Disease	94	China	clinicaltrials.gov
February 11, 2026	NCT07403604	Effect of Insulin Lowering on Lipogenesis	Columbia University	Phase 1	Recruiting	Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity	25	United States	clinicaltrials.gov
January 30, 2026	NCT07378280	Study to Investigate the Effect of L. Lactis CKDB001 Administration on Liver Aminotransferases in Subjects With NAFLD	Chuncheon Sacred Heart Hospital	Not applicable	Completed	Non Alcoholic Fatty Liver Disease	95	South Korea	clinicaltrials.gov
January 29, 2026	NCT07376486	Duodenal pulsENDO as an Early Treatment for Type 2 DM	Chinese University of Hong Kong	Not applicable	Recruiting	Diabete Mellitus, T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)	40	Hong Kong	clinicaltrials.gov
January 26, 2026	NCT07366710	Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET	Copenhagen University Hospital, Rigshospitalet	Not applicable	Active not recruiting	Glucose Metabolism, NAFLD (Nonalcoholic Fatty Liver Disease)	36	Denmark	clinicaltrials.gov
January 23, 2026	NCT07363707	A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes.	Beni-Suef University	Phase 4	Completed	NAFLD (Nonalcoholic Fatty Liver Disease)	108	Egypt	clinicaltrials.gov
January 22, 2026	NCT07358546	A Study of Efimosfermin Alfa in Adults With Hepatic Impairment	GlaxoSmithKline	Phase 1	Recruiting	Non-alcoholic Fatty Liver Disease	32	United States	clinicaltrials.gov
January 13, 2026	NCT07338331	Comparative Effects of Aspirin, Metformin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic...	Galala University	Not applicable	Completed	Diabete Type 2, Non Alcoholic Fatty Liver	80	Egypt	clinicaltrials.gov
January 13, 2026	NCT07336563	ENDOCARE-SCREEN: Metabolic Liver Dysfunction Screening Study	Jarosław Drobnik	Observational	Not yet recruiting	Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH), Metabolic...	10,000	Poland	clinicaltrials.gov
January 13, 2026	NCT07335198	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to...	GlaxoSmithKline	Phase 1	Completed	Non-alcoholic Fatty Liver Disease	30	New Zealand	clinicaltrials.gov
January 7, 2026	NCT07321925	Thermoacoustic Method for Estimating Liver Fat Fraction	Endra Lifesciences	Observational	Recruiting	MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated...	49	United States	clinicaltrials.gov
December 30, 2025	NCT07310407	Rutin and Vitamin C in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)	Ain Shams University	Phase 2	Not yet recruiting	NAFLD	120	Egypt	clinicaltrials.gov
December 29, 2025	NCT07308548	A Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH )	Hinova Pharmaceuticals Inc.	Phase 2	Recruiting	NAFLD (Non-alcoholic Fatty Liver Disease)	80	China	clinicaltrials.gov
December 19, 2025	NCT07294963	Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease	Khyber Medical University Peshawar	Not applicable	Completed	Non-Alcoholic Fatty Liver Disease, Neurocognitive Disorders	45	Pakistan	clinicaltrials.gov
December 17, 2025	NCT07288138	A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and...	Eccogene	Phase 2	Recruiting	Metabolic Dysfunction-associated Steatohepatitis	160	United States	clinicaltrials.gov
December 8, 2025	NCT07270601	Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis	ContextVision AB	Not applicable	Recruiting	MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, NAFLD - Non-Alcoholic Fatty Liver Disease	110	United States	clinicaltrials.gov
December 8, 2025	NCT07269197	Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes	Josip Juraj Strossmayer University of Osijek	Observational	Completed	Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2	67	Croatia	clinicaltrials.gov
December 8, 2025	NCT07268937	Assessment of Hepatic Steatosis Using Dedicated Software Implemented on Ultrasound Devices	Fondazione IRCCS Policlinico San Matteo di Pavia	Observational	Completed	Non-alcoholic Fatty Liver Disease (NAFLD)	25	Italy	clinicaltrials.gov
December 4, 2025	NCT07265297	Using Hydroxychloroquine (HCQ) to Treat Steatohepatitis	National Taiwan University Hospital	Phase 3	Recruiting	Steatohepatitis, Nonalcoholic	210	Taiwan	clinicaltrials.gov
December 4, 2025	NCT07265011	Ultrasound-Based Estimation of Hepatic Steatosis in Pediatric MASLD	Jae Won Choi	Not applicable	Completed	MASLD, Pediatric	50	South Korea	clinicaltrials.gov
December 1, 2025	NCT07255781	Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy	University of California, San Diego	Observational	Withdrawn	Psoriasis (PsO), PsA (Psoriatic Arthritis), NAFLD (Nonalcoholic Fatty Liver Disease)	0		clinicaltrials.gov
November 25, 2025	NCT07248371	Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related Diseases	Chang Gung Memorial Hospital	Observational	Recruiting	Metabolic Syndrome (MetS), Obesity & Overweight, Cardiovascular Diseases (CVD), Chronic Kidney Disease, Nonalcoholic...	6,266	Taiwan	clinicaltrials.gov
November 21, 2025	NCT07241195	A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic...	The Affiliated Hospital of Hangzhou Normal University	Observational	Recruiting	NAFLD and NASH, NAFLD( Non-alcoholic Fatty Liver Disease ), NAFLD Cirrhosis	20,000	China	clinicaltrials.gov
November 20, 2025	NCT07237750	iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) +Optimized Lifestyle Intervention (OLI) vs Sham + OLI for Weight Loss	Liu Yan	Not applicable	Recruiting	Overweight and/or Obesity, Metabolic Syndrome, Nonalcoholic Fatty Liver Disease	216	China	clinicaltrials.gov
October 27, 2025	NCT07221227	A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH	GlaxoSmithKline	Phase 3	Recruiting	Non-alcoholic Fatty Liver Disease	1,200	Australia, Canada, Hong Kong, Japan, New Zealand, Puerto Rico, Saudi Arabia...	clinicaltrials.gov
October 27, 2025	NCT07221188	A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or...	GlaxoSmithKline	Phase 3	Recruiting	Non-alcoholic Fatty Liver Disease	1,250	Australia, France, Germany, Hong Kong, Japan, New Zealand, Saudi Arabia, United...	clinicaltrials.gov
October 9, 2025	NCT07214870	A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat	Novo Nordisk A/S	Phase 1	Active not recruiting	Fatty Liver Disease	29	Canada	clinicaltrials.gov
October 1, 2025	NCT07200934	Effect of Adding TENS to Mediterranean Diet on Appetite and Liver Enzymes in Nonalcoholic Fatty Liver Patients	Cairo University	Not applicable	Completed	Nonalcoholic Fatty Liver	50	Egypt	clinicaltrials.gov
September 30, 2025	NCT07198516	The Improvement Effect of Henggliejin on Fatty Liver in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver:	Fujian Medical University Union Hospital	Early phase 1	Not yet recruiting	NAFLD, Diabete Type 2	149		clinicaltrials.gov
September 26, 2025	NCT07193927	Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A...	AB Biotics, SA	Phase 2	Recruiting	MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Fatty Liver Disease, Nonalcoholic, Overweight (BMI...	60	Spain	clinicaltrials.gov
September 19, 2025	NCT07182136	The Impact of Hepatic Steatosis on Survival After Pancreaticoduodenectomy	Wei-Hsun Lu	Observational	Completed	Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy	200		clinicaltrials.gov
September 18, 2025	NCT07180745	Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease	Badr University	Phase 4	Not yet recruiting	Non-alcoholic Fatty Liver Disease NAFLD, Non-alcoholic Steatohepatitis NASH	400	Egypt	clinicaltrials.gov
September 15, 2025	NCT07172997	Non-Invasive MASLD Diagnosis & T2D Remission Biomarkers	Royal College of Surgeons in Ireland - Medical University of Bahrain	Observational	Active not recruiting	MASLD, T2DM (Type 2 Diabetes Mellitus), Non-alcoholic Fatty Liver Disease (NAFLD), Obesity	163	Bahrain	clinicaltrials.gov
September 11, 2025	NCT07168551	Is There a Relationship Between Uric Acid Level and Liver Fibrosis in Obese Patients	Assiut University	Observational	Not yet recruiting	Hyperuricemia, NAFLD (Nonalcoholic Fatty Liver Disease), Liver Fibrosis	111		clinicaltrials.gov
September 10, 2025	NCT07165028	A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)	Eli Lilly and Company	Phase 3	Recruiting	Metabolic Dysfunction-Associated Steatotic Liver Disease	4,500	Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China...	clinicaltrials.gov
September 2, 2025	NCT07149571	To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in...	Tongji Hospital	Observational	Recruiting	Nonalcoholic Fatty Liver Disease, Metabolic-associated Fatty Liver Disease	500	China	clinicaltrials.gov
August 28, 2025	NCT07146815	PolyCystic Ovary Syndrome as Suggested Risk Group for Non-Alcoholic Fatty Liver Disease	Ziekenhuis Oost-Limburg	Not applicable	Completed	NAFLD (Nonalcoholic Fatty Liver Disease), Polycystic Ovarian Syndrome (PCOS)	157	Belgium	clinicaltrials.gov
August 19, 2025	NCT07130318	Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise	Cairo University	Not applicable	Recruiting	Familial Mediterranean Fever, Non-Alcoholic Fatty Liver Disease	40	Egypt	clinicaltrials.gov
August 19, 2025	NCT07128797	a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic...	Tasly Biopharmaceuticals Co., Ltd.	Phase 1	Recruiting	NAFLD (Non-alcoholic Fatty Liver Disease), NASH (Nonalcoholic Steatohepatitis)	32	China	clinicaltrials.gov
August 5, 2025	NCT07104786	Comparison of Effectiveness of Obeticholic Acid With Vitamin E in Patients of Non-alcoholic Fatty Liver Disease	King Edward Medical University	Phase 2	Completed	Non Alcoholic Fatty Liver Disease	90	Pakistan	clinicaltrials.gov
August 5, 2025	NCT07103603	MHT and Liver Function in Postmenopausal Women	Ipek B. Ozcivit Erkan, MD	Not applicable	Completed	Menopause, Non Alcholic Fatty Liver Disease, Hepatic Steatosis	44	Turkey (Türkiye)	clinicaltrials.gov
August 1, 2025	NCT07099118	A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects	Sunshine Lake Pharma Co., Ltd.	Phase 1	Recruiting	Non - Alcoholic Steatohepatitis	96	China	clinicaltrials.gov
July 30, 2025	NCT07093346	The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic...	University of Nottingham	Not applicable	Recruiting	Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD), MASLD - Metabolic Dysfunction-Associated...	45	United Kingdom	clinicaltrials.gov
July 25, 2025	NCT07086989	Cardiovascular Risk in Children With Chronic Conditions Study	Semmelweis University	Observational	Recruiting	Kidney Transplant, Familial Hypercholesterolaemia, Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM)...	300	Hungary	clinicaltrials.gov
July 17, 2025	NCT07070362	Digital Early Warning System for Acute Lung Injury in Liver Surgery	Beijing Tsinghua Chang Gung Hospital	Observational	Recruiting	Acute Lung Injury(ALI), Liver Cirrhosis, ARDS, Human, MASLD, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic...	3,000	China	clinicaltrials.gov
July 16, 2025	NCT07068191	Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly	Phenomen Pharma	Not applicable	Recruiting	Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly, Nonalcoholic Fatty Liver (NAFL)...	90	Russia	clinicaltrials.gov
July 4, 2025	NCT07051863	Prospective Cohort and Biobank of Patients With Nonalcoholic Fatty Liver Disease	Fondazione Epatocentro Ticino	Observational	Recruiting	NAFLD, MASH, NASH/MASH	300	Switzerland	clinicaltrials.gov
June 18, 2025	NCT07027332	Liver Stiffness And Steatosis Assessment In Women With Polycystic Ovary Syndrome Using Fibroscan	Bezmialem Vakif University	Observational	Completed	Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease	36	Turkey (Türkiye)	clinicaltrials.gov
June 17, 2025	NCT07024212	Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects	Zhejiang Doer Biologics Co., Ltd.	Phase 2	Active not recruiting	MASLD	110	China, Hong Kong	clinicaltrials.gov
June 15, 2025	NCT07021443	The Effect of GLP-1 Analogues on Liver Steatosis and Fibrosis in Diabetic and Obese Patients in a Clinical Setting	Universitair Ziekenhuis Brussel	Observational	Completed	Non-Alcoholic Fatty Liver Disease	50	Belgium	clinicaltrials.gov
June 13, 2025	NCT07020377	Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).	Amira Bisher,PhD	Phase 1/2	Active not recruiting	Diabetes Mellitus, Non Alcholic Fatty Liver Disease	60	Egypt	clinicaltrials.gov
June 6, 2025	NCT07007741	Digital Therapy for Fatty Liver Disease	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	Not applicable	Active not recruiting	Steatohepatitis, Nonalcoholic, Nonalcoholic Fatty Liver	141	China	clinicaltrials.gov
May 21, 2025	NCT06982378	GLP-1 RA on Liver OMICS in MASLD	Medical College of Wisconsin	Observational	Withdrawn	NAFLD, Diabetes, Obesity	0	United States	clinicaltrials.gov
May 16, 2025	NCT06975579	The COherence of Scatter Identification and Exclusion Algorithm Study	Institute of Cancer Research, United Kingdom	Observational	Recruiting	Steatohepatitis, Nonalcoholic	15	United Kingdom	clinicaltrials.gov

Sponsors posting most

Sponsor	New trials	Latest
Assiut University	8	October 6, 2026
Cairo University	6	September 22, 2026
GlaxoSmithKline	5	January 22, 2026
Regeneron Pharmaceuticals	4	October 2, 2026
Tanta University	3	October 28, 2026
Eccogene	3	October 14, 2026
University of Lahore	2	August 17, 2026
Zhejiang Doer Biologics Co., Ltd.	2	July 9, 2026
Chinese University of Hong Kong	2	June 23, 2026
Corcept Therapeutics	2	April 28, 2026
University of California, San Diego	2	April 9, 2026
Ain Shams University	2	December 30, 2025
Fondazione Policlinico Universitario Agostino Gemelli IRCCS	2	March 21, 2025
Federal State Budgetary Scientific Institution	2	December 10, 2024
Samsung Medical Center	1	November 6, 2026
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	1	November 4, 2026
Shanxi Bethune Hospital	1	October 21, 2026
Shalamar Hospital	1	October 19, 2026
Hanoi Medical University	1	September 22, 2026
Renmin Hospital of Wuhan University	1	September 17, 2026

By phase

Phase	New trials	Latest
Not applicable	51	November 6, 2026
Observational	50	November 4, 2026
Phase 1	14	October 14, 2026
Phase 2	12	June 9, 2026
Phase 3	9	October 2, 2026
Phase 4	4	January 23, 2026
Phase 2/3	2	October 28, 2026
Early phase 1	2	February 12, 2026
Phase 1/2	2	June 13, 2025

By country

Country	New trials	Latest
China	27	October 21, 2026
United States	21	October 2, 2026
Egypt	16	October 28, 2026
United Kingdom	8	June 8, 2026
Italy	7	June 12, 2026
Pakistan	6	October 19, 2026
Hong Kong	6	June 23, 2026
Australia	5	October 14, 2026
Turkey (Türkiye)	5	August 17, 2026
Spain	5	June 22, 2026
Canada	5	October 27, 2025
New Zealand	4	January 13, 2026
Taiwan	4	December 4, 2025
Germany	4	October 27, 2025
Belgium	4	September 10, 2025
Puerto Rico	3	June 8, 2026
France	3	March 27, 2026
South Korea	3	January 30, 2026
Japan	3	October 27, 2025
Switzerland	3	September 10, 2025
Finland	2	September 15, 2026
Norway	2	August 20, 2026
Denmark	2	January 26, 2026
Poland	2	January 13, 2026
Saudi Arabia	2	October 27, 2025

Where the register publishes

U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.

$10 of credit on sign-up, no card.

Get this list free